Comparative Pharmacology
Head-to-head clinical analysis: TECVAYLI versus TRISENOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECVAYLI versus TRISENOX.
TECVAYLI vs TRISENOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bispecific T-cell engager antibody that binds to BCMA on multiple myeloma cells and CD3 on T-cells, leading to T-cell activation and targeted cytotoxicity.
Arsenic trioxide induces apoptosis in acute promyelocytic leukemia (APL) cells by targeting the PML-RARα fusion protein, leading to its degradation and subsequent differentiation and apoptosis. It also generates reactive oxygen species, disrupts mitochondrial function, and activates caspases.
Subcutaneous injection: Step-up dosing schedule. First dose 0.06 mg/kg, then 0.3 mg/kg on day 4, followed by 1.5 mg/kg weekly starting day 7. Maximum single dose 1.5 mg/kg.
0.15 mg/kg IV daily until bone marrow remission, then 0.15 mg/kg IV 5 days/week for 2 weeks with 2 weeks off for up to 6 cycles.
None Documented
None Documented
22.5 days (range 10–35 days) based on population pharmacokinetic analysis; supports every-2-week dosing after step-up.
Terminal elimination half-life for inorganic arsenic is approximately 10-14 hours, with a mean of 12 hours. The methylated metabolites have longer half-lives, contributing to accumulation with repeated dosing. Clinical context: Supports daily dosing schedule with monitoring for toxicity.
Primarily catabolized to small peptides and amino acids; not expected to be excreted renally or hepatically to a significant extent.
Primarily renal excretion of unchanged arsenic (approximately 15-30% of the dose within 24 hours) with the remainder undergoing hepatic methylation to monomethylarsonic acid (MMA) and dimethylarsinic acid (DMA), which are excreted renally. Biliary and fecal elimination are minor (<5%).
Category C
Category C
Antineoplastic
Antineoplastic, Arsenic Trioxide